NCT03913234: Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

NCT03913234
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Male
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express BOTH HER2+ & HR+
Exclusions: Patients who have received treated with systemic treatment for metastatic breast cancer- see trial for details; Patients with central nervous system metastasis; Patients with inflammatory breast cancer
https://ClinicalTrials.gov/show/NCT03913234

Comments are closed.

Up ↑